A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Ryzneuta
Synonyms :
Efbemalenograstim alfa, benegrastim Bineuta F 627
Class :
Hematopoietic Growth Factors, fusion protein targeting CSF-3R (GCSFR), Granulocyte colony-stimulating factor (G-CSF/CSF3), Long acting dimeric granulocyte colony-stimulating factor (G-CSF)
Brand Name :
Ryzneuta
Synonyms :
Efbemalenograstim alfa, benegrastim Bineuta F 627
Class :
Hematopoietic Growth Factors, fusion protein targeting CSF-3R (GCSFR), Granulocyte colony-stimulating factor (G-CSF/CSF3), Long acting dimeric granulocyte colony-stimulating factor (G-CSF)
Refer to the adult dosing
Actions and Spectrum:
Actions:
A recombinant dimeric fusion peptide of human granulocyte colony-stimulating factor (G-CSF; filgrastim) having immunomodulatory and hematopoietic properties. Benegrastim binds to cell surface G-CSF receptors (G-CSFRs), causing receptor dimerization and activation of signaling cascades such as the Jak-STAT and mitogen-activated protein kinase pathways. This promotes neutrophil progenitor proliferation and differentiation.
Spectrum:
The spectrum of benegrastim extends from chemotherapy-induced neutropenia, parkinsonism, fever, breast cancer, and other conditions, if any.
N/A
Black Box Warning:
N/A
Contraindication/Caution:
Contraindications
Cautions
Pregnancy consideration:
No data is available regarding the administration of the drug during pregnancy.
Breastfeeding warnings:
No data is available regarding the excretion of drug in breast milk.
Pregnancy category:
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology:
Human granulocyte colony stimulating factor (rhG-CSF); dimeric recombinant fusion protein composed of two G-CSF molecules at the N-terminus of IgG2-Fc fragments.
By binding to cell surface G-CSF receptors (G-CSFRs) and inducing receptor dimerization and activation of signaling cascades (eg, Jak-STAT, mitogen-activated protein kinase pathways), it stimulates neutrophil progenitor proliferation and differentiation.
Pharmacodynamics:
N/A
Pharmacokinetics:
N/A
Administration:
N/A
Patient information leaflet
Generic Name: benegrastim
Pronounced: ben-uh-gras-tim
Why do we use benegrastim?
Benegrastim, also known as F-627, is a CSF-3R (GCSFR) fusion protein. Evive Biotech created it. Benegrastim is used to treat illnesses such as neutropenia, fever, breast cancer, Parkinson’s disease, and others.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
